Trial Profile
A Randomized, Open-label, Active-controlled, Parallel-group Study to Investigate the Platelet Inhibition of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus After Recent Elective Percutaneous Coronary Intervention
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ticagrelor (Primary) ; Aspirin; Clopidogrel
- Indications Coronary artery disease
- Focus Pharmacodynamics
- Acronyms PLATIDE-PCI
- 15 Jul 2020 Primary endpoint (P2Y12 reaction unit (PRU)) has been met as per results published in the Thrombosis and Haemostasis
- 15 Jul 2020 Results published in the Thrombosis and Haemostasis
- 19 Mar 2019 Status changed from recruiting to completed.